Migraine Medicine Competition: Teva Seeks To Halt Launch Of Emgality
Under emerging pricing strategy, Lilly will provide Emgality free for up to 12 months to commercially insured patients; Amgen has similar program for Aimovig.
You may also be interested in...
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor
The three US FDA-approved anti-CGRP antibodies for migraine prevention have similar efficacy and matching prices, but Lilly thinks access to Emgality – including through value-based arrangements – along with the biologic's ease of use and headache-free data will differentiate the product.
Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?
The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.